NSC-370284 (2.5 mg/kg; i.p., once daily for 10 days) improves the pathological morphologies in peripheral blood (PB), bone marrow (BM), spleen, and liver tissues in MLL-AF9 acute myeloid leukemia (AML) mice model[1].
| Animal Model: | C57BL/6 (CD45.2) and B6.SJL (CD45.1) mice[1]. |
| Dosage: | 2.5mg/kg. |
| Administration: | Intraperitoneal injection, once daily, for 10 days. |
| Result: | Significantly inhibited MLL-AF9 induced AML in secondary bone marrow transplantation (BMT) recipient mice. |
![1,3-Benzodioxol-5-ol,6-[1-pyrrolidinyl(3,4,5-trimethoxyphenyl)methyl]- Structure](/CAS/20180601/GIF/116409-29-1.gif)